Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The Secretary Department Of Atomic Energy is prosecuting a portfolio in the Biotechnology & Pharmaceuticals technology area. There is 1 pending office action currently active. This single matter represents the current focus of the department's patent activities.
The portfolio's prosecution involves 1 distinct examiner and 1 distinct art unit. This suggests that the technical scope of the filings is specialized and remains within a single administrative group at the USPTO. For the practitioner, this concentration eliminates the need to coordinate between different art units or manage multiple examiner styles.
BONAPARTE, AMY C is the busiest examiner for this portfolio, managing 1 busiest examiner pending office action. Because there is 1 pending office action in total, this examiner has sole oversight of the current active pipeline. The practitioner's strategy should be informed by the specific tendencies of this one official.
With 1 distinct examiner and 1 distinct art unit, the prosecution process is highly centralized. The practitioner can manage the 1 pending office action with a clear understanding of the single examiner's expectations. This focused approach allows for a more efficient prosecution of the department's biotechnology and pharmaceutical innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BONAPARTE, AMY C | 1 | 79.3% | +23.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18087427 | Deuterated 3,3'-Diselenodipropionic Acid (DSePA) and Its Use as an Anticancer or Radioprotective Agent | BONAPARTE, AMY C | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18087427 | Deuterated 3,3'-Diselenodipropionic Acid (DSePA) and Its Use as an Anticancer or Radioprotective Agent | BONAPARTE, AMY C | 5d |
| Art Unit | Apps |
|---|---|
| 1692 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18087427 | Deuterated 3,3'-Diselenodipropionic Acid (DSePA) and Its Use as an Anticancer or Radioprotective Agent | BONAPARTE, AMY C | 1692 | §103§112 | Final Rejection | 5d | Pending | Dec 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial